Ascendis a new outperform at BMO on TransCon platform growth
· seekingalpha.com
BMO starts Ascendis Pharma (ASND) at outperform with $319 target, citing TransCon platform growth and Yorvipath as key driver. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...